当前位置: 首页 > 详情页

Pacing or Ablation: Which Is Better for Paroxysmal Atrial Fibrillation-Related Tachycardia-Bradycardia Syndrome?

文献详情

资源类型:

收录情况: ◇ SCIE

机构: [1]Capital Med Univ, Beijing An Zhen Hosp, Dept Cardiol, Beijing 100029, Peoples R China; [2]Capital Med Univ, Beijing Anzhen Hosp, Dept Cardiol, 2 An Zhen Rd, Beijing 100029, Peoples R China
出处:
ISSN:

关键词: sinus node dysfunction atrial fibrillation catheter ablation pacemaker

摘要:
Background Symptomatic prolonged sinus pauses on termination of atrial fibrillation (AF) are an accepted indication for pacemaker implantation. We evaluated the outcome of AF ablation in patients with paroxysmal AF-related tachycardia-bradycardia syndrome and compared the efficacy of catheter ablation with permanent pacing plus antiarrhythmic drugs (AADs). Methods and Results Patients with prolonged symptomatic sinus pauses on termination of AF were retrospectively analyzed. Forty-three consecutive patients who underwent catheter ablation (ABL group) were compared to 57 patients who underwent permanent pacing plus AADs (PM group). All 43 patients in the ABL group fulfilled Class I indication for pacemaker implantation at baseline but they actually underwent AF ablation. Reevaluation after 20.1 +/- 9.6 months of follow-up showed that 41 patients (95.3%) did no longer need a pacemaker (Class III indication). Total cardiac-related rehospitalization was not significantly different between the two groups (P = 0.921). Tachycardia-related hospitalization was significantly higher in the PM group than the ABL group (14.0% and 0%, P = 0.029). More patients in the PM group were on AADs (PM 40.4%, ABL 4.7%, P < 0.001) while sinus rhythm maintenance was remarkably higher in the ABL group at the end of follow-up (83.7% vs 21.1% in PM group, P < 0.001). Conclusions In patients with paroxysmal AF-related tachycardia-bradycardia syndrome, AF ablation seems to be superior to a strategy of pacing plus AAD. Pacemaker implantation can be waived in the majority of patients after a successful ablation.

语种:
被引次数:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2013]版:
大类 | 4 区 医学
小类 | 4 区 心脏和心血管系统 4 区 工程:生物医学
最新[2023]版:
大类 | 4 区 医学
小类 | 4 区 心脏和心血管系统 4 区 工程:生物医学
JCR分区:
出版当年[2012]版:
Q2 ENGINEERING, BIOMEDICAL Q3 CARDIAC & CARDIOVASCULAR SYSTEMS
最新[2023]版:
Q3 CARDIAC & CARDIOVASCULAR SYSTEMS Q3 ENGINEERING, BIOMEDICAL

影响因子: 最新[2023版] 最新五年平均 出版当年[2012版] 出版当年五年平均 出版前一年[2011版] 出版后一年[2013版]

第一作者:
第一作者机构: [1]Capital Med Univ, Beijing An Zhen Hosp, Dept Cardiol, Beijing 100029, Peoples R China;
通讯作者:
通讯机构: [1]Capital Med Univ, Beijing An Zhen Hosp, Dept Cardiol, Beijing 100029, Peoples R China; [2]Capital Med Univ, Beijing Anzhen Hosp, Dept Cardiol, 2 An Zhen Rd, Beijing 100029, Peoples R China
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:16409 今日访问量:0 总访问量:869 更新日期:2025-01-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 首都医科大学宣武医院 技术支持:重庆聚合科技有限公司 地址:北京市西城区长椿街45号宣武医院